Young African Innovators Lack Investment Not Creativity, Awards Ceremony Told 16/09/2021 Madeleine Hoecklin Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday. The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical […] Continue reading -> ‘High Hopes’ of WTO Action to Curb Harmful Fisheries Subsidies & Stimulate Pandemic Response – But Decisions Punted to Autumn 27/07/2021 Elaine Ruth Fletcher World Trade Organization Director General Ngozi Okonjo-Iweala has ” high hopes” that the WTO Ministerial Conference (MC12) that convenes at the end of November can deliver decisions that curb harmful fisheries subsidies as well as improving access of low- and middle-income countries to COVID medicines and vaccines. But WTO members must overcome a series of […] Continue reading -> New Global Recommendations for Human Genome Editing may Improve Use to Cure and Treat Diseases 12/07/2021 Madeleine Hoecklin Human genome editing has great potential to improve health and serve as a tool for public health, according to two landmark WHO reports, the world’s first to issue global recommendations on the safe, effective, and ethical use of human genome editing. “These new reports from WHO’s Expert Advisory Committee represent a leap forward for this […] Continue reading -> Finally, Therapeutics for Severe COVID-19 – But They Come With Hefty Price Tags 06/07/2021 Kerry Cullinan After months with virtually no therapeutic options for people with severe COVID-19, the World Health Organization (WHO) recommended the use of a class of medicines called interleukin-6 antagonists on Tuesday. The medicines, tocilizumab and sarilumab, reduced the risk of death and ventilation when combined with corticosteroids, according to a study published the same day in […] Continue reading -> Forty New Medicines & 16 New Indications Under Consideration For WHO Essential Medicines List 21/06/2021 Elaine Ruth Fletcher Proposals to incorporate some 40 new medications in WHO’s Essential Medicines List – from complex cancer treatments to new medicines for hepatitis C and rabies – will be examined over the coming two weeks by the EML Expert Committee. The Committee, which kicked off its deliberations on Monday with a public hearing, also will consider […] Continue reading -> Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
‘High Hopes’ of WTO Action to Curb Harmful Fisheries Subsidies & Stimulate Pandemic Response – But Decisions Punted to Autumn 27/07/2021 Elaine Ruth Fletcher World Trade Organization Director General Ngozi Okonjo-Iweala has ” high hopes” that the WTO Ministerial Conference (MC12) that convenes at the end of November can deliver decisions that curb harmful fisheries subsidies as well as improving access of low- and middle-income countries to COVID medicines and vaccines. But WTO members must overcome a series of […] Continue reading -> New Global Recommendations for Human Genome Editing may Improve Use to Cure and Treat Diseases 12/07/2021 Madeleine Hoecklin Human genome editing has great potential to improve health and serve as a tool for public health, according to two landmark WHO reports, the world’s first to issue global recommendations on the safe, effective, and ethical use of human genome editing. “These new reports from WHO’s Expert Advisory Committee represent a leap forward for this […] Continue reading -> Finally, Therapeutics for Severe COVID-19 – But They Come With Hefty Price Tags 06/07/2021 Kerry Cullinan After months with virtually no therapeutic options for people with severe COVID-19, the World Health Organization (WHO) recommended the use of a class of medicines called interleukin-6 antagonists on Tuesday. The medicines, tocilizumab and sarilumab, reduced the risk of death and ventilation when combined with corticosteroids, according to a study published the same day in […] Continue reading -> Forty New Medicines & 16 New Indications Under Consideration For WHO Essential Medicines List 21/06/2021 Elaine Ruth Fletcher Proposals to incorporate some 40 new medications in WHO’s Essential Medicines List – from complex cancer treatments to new medicines for hepatitis C and rabies – will be examined over the coming two weeks by the EML Expert Committee. The Committee, which kicked off its deliberations on Monday with a public hearing, also will consider […] Continue reading -> Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Global Recommendations for Human Genome Editing may Improve Use to Cure and Treat Diseases 12/07/2021 Madeleine Hoecklin Human genome editing has great potential to improve health and serve as a tool for public health, according to two landmark WHO reports, the world’s first to issue global recommendations on the safe, effective, and ethical use of human genome editing. “These new reports from WHO’s Expert Advisory Committee represent a leap forward for this […] Continue reading -> Finally, Therapeutics for Severe COVID-19 – But They Come With Hefty Price Tags 06/07/2021 Kerry Cullinan After months with virtually no therapeutic options for people with severe COVID-19, the World Health Organization (WHO) recommended the use of a class of medicines called interleukin-6 antagonists on Tuesday. The medicines, tocilizumab and sarilumab, reduced the risk of death and ventilation when combined with corticosteroids, according to a study published the same day in […] Continue reading -> Forty New Medicines & 16 New Indications Under Consideration For WHO Essential Medicines List 21/06/2021 Elaine Ruth Fletcher Proposals to incorporate some 40 new medications in WHO’s Essential Medicines List – from complex cancer treatments to new medicines for hepatitis C and rabies – will be examined over the coming two weeks by the EML Expert Committee. The Committee, which kicked off its deliberations on Monday with a public hearing, also will consider […] Continue reading -> Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Finally, Therapeutics for Severe COVID-19 – But They Come With Hefty Price Tags 06/07/2021 Kerry Cullinan After months with virtually no therapeutic options for people with severe COVID-19, the World Health Organization (WHO) recommended the use of a class of medicines called interleukin-6 antagonists on Tuesday. The medicines, tocilizumab and sarilumab, reduced the risk of death and ventilation when combined with corticosteroids, according to a study published the same day in […] Continue reading -> Forty New Medicines & 16 New Indications Under Consideration For WHO Essential Medicines List 21/06/2021 Elaine Ruth Fletcher Proposals to incorporate some 40 new medications in WHO’s Essential Medicines List – from complex cancer treatments to new medicines for hepatitis C and rabies – will be examined over the coming two weeks by the EML Expert Committee. The Committee, which kicked off its deliberations on Monday with a public hearing, also will consider […] Continue reading -> Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Forty New Medicines & 16 New Indications Under Consideration For WHO Essential Medicines List 21/06/2021 Elaine Ruth Fletcher Proposals to incorporate some 40 new medications in WHO’s Essential Medicines List – from complex cancer treatments to new medicines for hepatitis C and rabies – will be examined over the coming two weeks by the EML Expert Committee. The Committee, which kicked off its deliberations on Monday with a public hearing, also will consider […] Continue reading -> Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Technical Fixes or Sweeping Reform? Europe and Developing Countries Face Uphill Battle to Etch Consensus on IP Waiver 18/06/2021 Elaine Ruth Fletcher Proponents of a sweeping World Trade Organization ‘waiver’ on intellectual property rights for all COVID-19 treatments, tests and vaccines face an uphill battle to reach consensus on a text ahead of a WTO General Council meeting scheduled for 27-28 July. This is despite the recent agreement of the initiative’s opponents, including the European Union, Korea, […] Continue reading -> Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions 18/06/2021 Svĕt Lustig Vijay From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2. At the same time, […] Continue reading -> More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
More Than Cables & Devices: Digital Health Event Points to Human Factors 28/05/2021 Svĕt Lustig Vijay In two decades of work on World Bank digital health initiatives, global health policy specialist Akiko Maeda found many fell short of their promises. She suggested these underperforming digital health initiatives focused too much on delivering hardware — but they failed to provide means to ensure stable electricity supplies, and similarly failed to provide adequate […] Continue reading -> The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The 1 Billion Dose Wager on the IP Waiver 21/05/2021 Elaine Ruth Fletcher & Svĕt Lustig Vijay Rich countries need to cough up 1 billion vaccine doses by September, and big pharma should significantly expand its network of voluntary license sharing and manufacturing – in order to avoid a vote by World Trade Organization members on a controversial proposal to waive all COVID-related intellectual property for the duration of the pandemic. That […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> Posts navigation Older postsNewer posts